Aims Stem cell therapy is a treatment strategy for ischaemic heart disease patients. Meta-
analysis of randomized human trials showed< 5% improvement in left ventricular ejection …

Stem cells provide an alternative curative intervention for the infarcted heart by
compensating for the cardiomyocyte loss subsequent to myocardial injury. The presence of …

Injectable hydrogels derived from the extracellular matrix (ECM) of decellularized tissues
have recently emerged as scaffolds for tissue-engineering applications. Here, we introduce …

Akt is a major cell survival and angiogenic mediator downstream of angiopoietin-1 (Ang-
1)/Tie-2 signaling pathway. We hypothesize that transplantation of mesenchymal stem cells …

Strategies to enhance skeletal myoblast (SkM) survival after transplantation in the ischemic
heart have achieved little success. We posit that preconditioned (PC) SkMs show improved …

Current pharmacologic therapy for ischemic heart disease suffers multiple limitations such
as compliance issues and side effects of medications. Revascularization procedures often …

Myocardial infarction (MI) affects millions of people worldwide. MI causes massive cardiac
cell death and heart function decrease. However, heart tissue cannot effectively regenerate …

Introduction: The characterization of multipotent endogenous cardiac stem cells (eCSCs)
and the breakthroughs of somatic cell reprogramming to boost cardiomyocyte replacement …

Rationale: Skeletal myoblasts (SMs) with inherent myogenic properties are better
candidates for reprogramming to pluripotency. Objective: To reprogram SMs to pluripotency …

Cardiomyocytes respond to physiological or pathological stress only by hypertrophy and not
by an increase in the number of functioning cardiomyocytes. However, recent evidence …